Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCS) Notes Payables (2022 - 2026)

HeartSciences filings provide 5 years of Notes Payables readings, the most recent being $3.1 million for Q1 2026.

  • On a quarterly basis, Notes Payables rose 22.7% to $3.1 million in Q1 2026 year-over-year; TTM through Jan 2026 was $3.1 million, a 22.7% increase, with the full-year FY2025 number at $2.6 million, up 410.23% from a year prior.
  • Notes Payables hit $3.1 million in Q1 2026 for HeartSciences, up from $500000.0 in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $3.1 million in Q1 2026 to a low of $130000.0 in Q3 2022.
  • Median Notes Payables over the past 5 years was $1.1 million (2022), compared with a mean of $1.3 million.
  • The widest YoY moves for Notes Payables: up 410.23% in 2025, down 78.87% in 2025.
  • HeartSciences' Notes Payables stood at $1.1 million in 2022, then grew by 25.41% to $1.4 million in 2023, then skyrocketed by 67.01% to $2.4 million in 2024, then tumbled by 78.87% to $500000.0 in 2025, then skyrocketed by 519.94% to $3.1 million in 2026.
  • The last three reported values for Notes Payables were $3.1 million (Q1 2026), $500000.0 (Q4 2025), and $1.5 million (Q3 2025) per Business Quant data.